Anchiano Therapeutics Ltd Stock TEL AVIV STOCK EXCHANGE

ANCN

IL0011267882

Delayed TEL AVIV STOCK EXCHANGE Other stock markets 09:24:34 2019-06-16 am EDT			5-day change	1st Jan Change
290.7 ^ILa	-.--%		-6.23%	-68.96%

2021	DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus	MT
2021	Anchiano Therapeutics : Shareholders OK Pending Chemomab Merger	MT

Chart Anchiano Therapeutics Ltd

Duration

Period

Style

Dynamic Chart

Latest news about Anchiano Therapeutics Ltd

DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus	21-03-16	MT
Anchiano Therapeutics : Shareholders OK Pending Chemomab Merger	21-03-16	MT
Anchiano Therapeutics Ltd.(NasdaqCM:ANCN) dropped from NASDAQ Composite Index	21-03-16	CI
ChemomAb Ltd. completed the acquisition of Anchiano Therapeutics Ltd. in a reverse merger transaction.	21-03-15	CI
Anchiano Therapeutics Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-09	CI
Anchiano Therapeutics Ltd. Auditor Raises 'Going Concern' Doubt	21-03-08	CI
Anchiano Therapeutics : Chemomab Plan Merger to Advance Treatment for Fibrosis-Related Diseases	20-12-15	MT
Anchiano Therapeutics Ltd. and Chemomab Ltd. Announce Executive Appointments	20-12-15	CI
ChemomAb Ltd. entered into letter of intent to acquire Anchiano Therapeutics Ltd. for for $27.2 million in a reverse merger transaction.	20-12-14	CI
Anchiano Therapeutics Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-16	CI
Anchiano Therapeutics Ltd Appoints Neil Cohen as Chief Executive Officer	20-10-20	CI
Anchiano Therapeutics Ltd Appoints Andrew Fine as the Chief Financial Officer	20-10-20	CI
Anchiano Therapeutics Ltd Announces Board Changes	20-10-20	CI
Anchiano Therapeutics Ltd Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-14	CI
Anchiano Therapeutics Ltd Announces Resignation of Frank Haluska as CEO	20-07-09	CI

More news

Analyst Recommendations on Anchiano Therapeutics Ltd

DJ Industrial : Wall Street Narrowly Mixed; Data, Fed Rate Meeting in Focus

21-03-16

More recommendations

Press releases Anchiano Therapeutics Ltd

ANCHIANO THERAPEUTICS LTD. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	21-03-17	AQ
Anchiano Announces Shareholder Approval of the Merger with Chemomab and Prices $45.5M Private Financing	21-03-15	GL
ANCHIANO THERAPEUTICS LTD. : Other Events (form 8-K)	21-03-10	AQ
ANCHIANO THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K)	21-03-09	AQ
ANCHIANO THERAPEUTICS LTD. : Other Events (form 8-K)	21-02-08	AQ

More press releases

Chemomab Therapeutics Ltd, formerly known as Anchiano Therapeutics Ltd, is a Israel-based biopharmaceutical company. The Company specializes in the development of patient oriented targeted therapy for the treatment of a wide range of cancers. Its therapeutic and diagnostic technology, BC-819, constitutes a search paradigm for the targeted destruction of cancer cells with no effect on surrounding tissue and no observed side effects for long-term, safe treatment and prevention of cancer. The patient oriented targeted therapy approach is based on the identification of particular genes that are expressed only in tumors.

Sector

More about the company